Skip to main content
SpringerLink
Log in

Efficacy and Safety of Osteoporosis Treatment

  • Chapter
  • First Online:
Pocket Reference to Osteoporosis

Abstract

For postmenopausal women with osteoporosis, pharmacological therapy compliments adequate nutrition, regular physical activity, and, when appropriate, strategies to prevent falls, alleviate pain, and optimize function. The objective of drug therapy is to reduce the incidence of serious fragility fractures that can impair function, degrade quality of life, and even increase the risk of death. Several drugs with different mechanisms of action are available for clinical use. This chapter will review the effectiveness, important safety issues, and practical considerations in choosing among the most important treatment options. Salmon calcitonin (limited evidence of efficacy and no longer available in Europe) and strontium ranelate (modest evidence of efficacy, significant restrictions on use in Europe, and never available in the United States) will not be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–41.

    Article  CAS  Google Scholar 

  2. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344–52.

    Article  CAS  Google Scholar 

  3. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333–40.

    Article  CAS  Google Scholar 

  4. Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–9.

    Article  CAS  Google Scholar 

  5. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.

    Article  CAS  Google Scholar 

  6. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.

    Article  CAS  Google Scholar 

  7. Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–7.

    Article  Google Scholar 

  8. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637–45.

    Article  CAS  Google Scholar 

  9. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923–34.

    Article  CAS  Google Scholar 

  10. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006;12:6222s–30s.

    Article  CAS  Google Scholar 

  11. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–99.

    Article  CAS  Google Scholar 

  12. Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75:462–8.

    Article  Google Scholar 

  13. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30:934–44.

    Article  CAS  Google Scholar 

  14. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008;19:365–72.

    Article  CAS  Google Scholar 

  15. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38.

    Article  CAS  Google Scholar 

  16. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243–54.

    Article  CAS  Google Scholar 

  17. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126:13–20.

    Article  CAS  Google Scholar 

  18. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis–where do we go from here? N Engl J Med. 2012;366:2048–51.

    Article  CAS  Google Scholar 

  19. Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med. 2003;348:1503–4.

    Article  Google Scholar 

  20. Fosamax Prescribing Information. Merck & Co, Inc; 2012.

    Google Scholar 

  21. Actonal Prescribing Information. Warner-Chilcott US, LLC; 2015.

    Google Scholar 

  22. Reclast Prescribing Information. Novartis Pharmaceuticals Corp; 2015.

    Google Scholar 

  23. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–809.

    Article  CAS  Google Scholar 

  24. Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int. 2011;22:983–91.

    Article  CAS  Google Scholar 

  25. Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res. 2013;28:2049–59.

    Article  CAS  Google Scholar 

  26. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281:2189–97.

    Article  CAS  Google Scholar 

  27. Evista Prescribing Information. Eli Lilly and Company; 2011.

    Google Scholar 

  28. Conbriza Prescribing Information [EMA]. Pfizer Limited; 2014.

    Google Scholar 

  29. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE randomized trial. JAMA. 2002;287:847–57.

    Article  CAS  Google Scholar 

  30. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–31.

    Article  CAS  Google Scholar 

  31. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513–23.

    Article  CAS  Google Scholar 

  32. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72–81.

    Article  CAS  Google Scholar 

  33. Prolia Prescribing Information. Amgen Inc; 2017.

    Google Scholar 

  34. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26:1829–35.

    Article  CAS  Google Scholar 

  35. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222–9.

    Article  CAS  Google Scholar 

  36. Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33:190–8.

    Article  CAS  Google Scholar 

  37. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.

    Article  CAS  Google Scholar 

  38. Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K. Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone. 2012;50:165–70.

    Article  CAS  Google Scholar 

  39. Forteo Prescribing Information. Eli Lilly and Company; 2012.

    Google Scholar 

  40. Kendler DL, Marin F, CAF Z, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2017.; pii: S0140-6736(17)32137-2

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oregon Osteoporosis Center, Portland, OR, USA

    Michael R. McClung

Authors
  1. Michael R. McClung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael R. McClung .

Editor information

Editors and Affiliations

  1. Division of Bone Diseases, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland

    Serge Livio Ferrari

  2. Department of Rheumatology, Paris Descartes University Cochin Hospital, Paris, France

    Christian Roux

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

McClung, M.R. (2019). Efficacy and Safety of Osteoporosis Treatment. In: Ferrari, S., Roux, C. (eds) Pocket Reference to Osteoporosis. Springer, Cham. https://doi.org/10.1007/978-3-319-26757-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26757-9_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26755-5

  • Online ISBN: 978-3-319-26757-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation